- Home
- KALV vs INMD Comparison
KALV vs INMD Comparison
Compare KALV & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- INMD
- Stock Information
- Founded
- KALV N/A
- INMD 2008
- Country
- KALV United States
- INMD Israel
- Employees
- KALV N/A
- INMD N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- INMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- KALV Health Care
- INMD Health Care
- Exchange
- KALV Nasdaq
- INMD Nasdaq
- Market Cap
- KALV 796.4M
- INMD 896.9M
- IPO Year
- KALV N/A
- INMD 2019
- Fundamental
- Price
- KALV $13.50
- INMD $14.96
- Analyst Decision
- KALV Strong Buy
- INMD Hold
- Analyst Count
- KALV 8
- INMD 6
- Target Price
- KALV $26.43
- INMD $16.81
- AVG Volume (30 Days)
- KALV 1.0M
- INMD 926.5K
- Earning Date
- KALV 09-11-2025
- INMD 10-29-2025
- Dividend Yield
- KALV N/A
- INMD N/A
- EPS Growth
- KALV N/A
- INMD 46.63
- EPS
- KALV N/A
- INMD 2.54
- Revenue
- KALV $1,426,000.00
- INMD $401,561,000.00
- Revenue This Year
- KALV N/A
- INMD N/A
- Revenue Next Year
- KALV $213.43
- INMD $5.30
- P/E Ratio
- KALV N/A
- INMD $5.89
- Revenue Growth
- KALV N/A
- INMD N/A
- 52 Week Low
- KALV $7.30
- INMD $13.14
- 52 Week High
- KALV $17.28
- INMD $19.85
- Technical
- Relative Strength Index (RSI)
- KALV 44.26
- INMD 53.79
- Support Level
- KALV $13.26
- INMD $14.86
- Resistance Level
- KALV $17.28
- INMD $15.48
- Average True Range (ATR)
- KALV 1.03
- INMD 0.41
- MACD
- KALV -0.10
- INMD 0.00
- Stochastic Oscillator
- KALV 9.13
- INMD 56.48
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.